AMPLITUDE-O: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

Rationale : The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on
cardiovascular and renal outcomes in patients with type 2 diabetes who are also at
high risk for adverse cardiovascular events is uncertain.

Infographic

Reference

Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K; AMPLITUDE-O Trial Investigators. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021 Sep 2;385(10):896-907.